Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Market
0.0%
Details
- Resolved Date
- 11/3/23
- Study Completion
- 2/3/26
- Company
- Seagen, a wholly owned subsidiary of Pfizer
- Ticker
- PFE
- Type
- Trial Status
- Completed
- Trial Size
- 161
- Volume
- $0
- NCT
- NCT04609566
- Drug Description
- This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.
Resolution Evidence
- Outcome
- YES
- Status
- Resolved
- Settlement Date
- 4/1/26 UTC
- Executive Summary
Public sources for NCT04609566 frame this Phase 2 study positively. The sponsor said the combination data were "intriguing" and supported continued research, and the later peer-reviewed paper concluded the trial showed clinically meaningful, durable responses with encouraging survival, supporting activity of the regimen.
Sources
Sponsorbusinesswire.com11/3/23
Seagen Highlights First Solid Tumor Data for an ADCETRIS Immunotherapy Combination at SITC
Sponsor described initial Phase 2 NCT04609566 data as intriguing and said the ADCETRIS+pembrolizumab combination supported continued research; safety was consistent with prior studies.
View source
Web Searchpmc.ncbi.nlm.nih.gov1/7/25
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic NSCLC and Melanoma
Peer-reviewed report for SGN35-033/NCT04609566 concluded the regimen produced clinically meaningful, durable responses with encouraging OS/PFS, supporting activity in anti–PD-1-refractory solid tumors.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
